Of the recently completed studies, two sister trials, CheckMate-49829 and CheckMate-54830, evaluated the addition of PD-1 inhibitor Nivolumab to the adjuvant chemoradiation for glioblastoma with unmethylated and methylated MGMT promoter, respectively. This evidence concerns the gene MGMT and glioblastoma.